CONCLUSIONS
Benralizumab (anti-IL-5 receptor antibody) significantly reduces the
size of nasal polyps, nasal blockage score, and rates of anosmia after
20 weeks therapy compared to baseline. The ratio of blood eosinophil to
positive allergen skin prick tests may help predict which patients
benefit the most from this biologic therapy.
Acknowledgement : We thank Jeanne Hoddinott, RN for her
excellent clinical and technical assistance.